Key result
Structural analysis of RV-A2 2Apro reveals a conserved hydrophobic pocket for broad-spectrum anti-enteroviral inhibitors.
Why the study?
Human rhinoviruses cause significant respiratory disease, but variations in sequence and substrate specificity between genetic groups A and B hinder rhinoviral 2A proteinase as a drug target.
The identification of a conserved hydrophobic P4 pocket in the RV-A2 2Apro structure complexed with zVAM.fmk provides a potential target for broad-spectrum anti-enteroviral inhibitors.
May guide inhibitor design against enteroviruses; leaves open whether targeting the P4 pocket yields effective therapies.
Picornavirus family members cause disease in humans. Human rhinoviruses (RV), the main causative agents of the common cold, increase the severity of asthma and COPD; hence, effective agents against RVs are required. The 2A proteinase (2Apro), found in all enteroviruses, represents an attractive target; inactivating mutations in poliovirus 2Apro result in an extension of the VP1 protein preventing infectious virion assembly. Variations in sequence and substrate specificity on eIF4G isoforms between RV 2Apro of genetic groups A and B hinder 2Apro as drug targets. Here, we demonstrate that although RV-A2 and RV-B4 2Apro cleave the substrate GAB1 at different sites, the 2Apro from both groups cleave equally efficiently an artificial site containing P1 methionine. We determined the RV-A2 2Apro structure complexed with zVAM.fmk, containing P1 methionine. Analysis of this first 2Apro-inhibitor complex reveals a conserved hydrophobic P4 pocket among enteroviral 2Apro as a potential target for broad-spectrum anti-enteroviral inhibitors.
No takes yet. Share an insight, caveat, or question.
Olek et al. (2021) studied Human rhinovirus infection. zVAM.fmk was evaluated on Crystal structure and substrate specificity of RV 2Apro. Structural analysis of the RV-A2 2Apro complexed with zVAM.fmk reveals a conserved hydrophobic P4 pocket among enteroviral 2Apro as a potential target for broad-spectrum anti-enteroviral inhibitors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: